Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 3:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,138 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: AIDS/HIV Clear all
Completed No phase listed Observational

Lung HIV Disease in a Large Cohort-Pitt

NCT01326572
View directory record Official record
Conditions
Pulmonary Disease, HIV, Emphysema
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 72 Years · Male only
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 28, 2026, 3:53 PM EDT
Recruiting Not applicable Interventional

Alcohol Research in HIV: Relapse Prevention

NCT05163301
View directory record Official record
Conditions
HIV, Alcohol Use Disorder
Interventions
Relapse Prevention Intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Reducing High Risk Behavior in Treatment Court

NCT01481428
View directory record Official record
Conditions
Substance Abuse, HIV
Interventions
Computer-facilitated HIV intervention, Attention Control
Behavioral
Lead sponsor
Treatment Research Institute
Other
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 28, 2026, 3:53 PM EDT
Completed No phase listed Observational

The Prevalence of Oral HPV Infection and Oral Lesions in People Living With HIV

NCT06205511
View directory record Official record
Conditions
Human Immunodeficiency Virus, Human Papilloma Virus
Interventions
Oral HPV Sample
Diagnostic Test
Lead sponsor
Vivent Health
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Denver, Colorado • St Louis, Missouri • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 28, 2026, 3:53 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

SER Familia: A Family-Based Intervention Addressing Syndemic Conditions Among Latino Families

NCT06627764
View directory record Official record
Conditions
Substance Abuse, Intimate Partner Violence (IPV), HIV Infections, Depression, Anxiety
Interventions
SER Familia
Behavioral
Lead sponsor
Duke University
Other
Eligibility
12 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP

NCT00076037
View directory record Official record
Conditions
HIV Infections
Interventions
HIV CTL MEP administered with RC529-SE adjuvant, GM-CSF
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 2 Interventional

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

NCT00000912
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
44
States / cities
Los Angeles, California • Menlo Park, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 1 Interventional

Effects of BufferGel and PRO 2000/5 Gel in Men

NCT00016536
View directory record Official record
Conditions
HIV Infections
Interventions
Naphthalene 2-sulfonate polymer, Carbopol polymer
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.

NCT00001044
View directory record Official record
Conditions
HIV Infections
Interventions
Aluminum hydroxide, QS-21, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1995
U.S. locations
4
States / cities
St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 1 Interventional

Genetically Modified Lymphocytes to Treat HIV-Infected Identical Twins - Study Modifications

NCT00001409
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infection
Interventions
Interleukin-2
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 4 Interventional Results available

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

NCT00084136
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Didanosine (enteric-coated), Efavirenz, Emtricitabine, Emtricitabine/Tenofovir disoproxil fumarate, Lamivudine/Zidovudine
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
1,571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
27
States / cities
Los Angeles, California • Torrance, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children

NCT00000893
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 16 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
25
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Not applicable Interventional

Trauma Informed Intervention to Support Engagement in HIV Care Among MSM (THRIVE+)

NCT05822206
View directory record Official record
Conditions
HIV/AIDS, Trauma
Interventions
CBT-TSC, Life Steps and Sexual Decision-Making
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Results available

Zaleplon in HIV Patients With Depression

NCT03489304
View directory record Official record
Conditions
HIV/AIDS, Clinical Depression
Interventions
Zaleplon
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults

NCT00001052
View directory record Official record
Conditions
HIV Infections
Interventions
Aluminum hydroxide, QS-21, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1997
U.S. locations
5
States / cities
St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Early Phase 1 Interventional

Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals

NCT01836068
View directory record Official record
Conditions
HIV
Interventions
Enfuvirtide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 28, 2026, 3:53 PM EDT
Recruiting Not applicable Interventional

The Less is More Study

NCT05153811
View directory record Official record
Conditions
Alcohol Use
Interventions
Counseling, mHealth
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
35 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Coral Gables, Florida • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Socio-Structural Intervention to Improve Pre-Exposure Prophylaxis Services for Cisgender Women

NCT07318532
View directory record Official record
Conditions
HIV Prevention Program
Interventions
The women's PrEP Project (W-PrEP)
Behavioral
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
Female only
Enrollment
745 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 28, 2026, 3:53 PM EDT
Completed No phase listed Observational

Observational Study of Solid Organ Transplantation Utilizing HIV-Positive Donors in HIV-Positive Recipients

NCT03170414
View directory record Official record
Conditions
HIV, Awaiting Organ Transplant
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
10 participants
Timeline
2017 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Diagnostic HIV Ag/Ab Combo Assay

NCT00933933
View directory record Official record
Conditions
Human Immunodeficiency Viruses
Interventions
ARCHITECT HIV Ag/Ab Combo
Device
Lead sponsor
Abbott Diagnostics Division
Industry
Eligibility
Not listed
Enrollment
635 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
13
States / cities
Phoenix, Arizona • St. Petersburg, Florida • Springfield, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Oct 28, 2026, 3:53 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating an Interactive Digital Toolkit for Women's PrEP Implementation

NCT07292584
View directory record Official record
Conditions
HIV Prevention, HIV Risk, Sexual and Reproductive Health
Interventions
Interactive Digital PrEP Toolkit
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
4
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tuscaloosa, Alabama + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.

NCT00386347
View directory record Official record
Conditions
HIV Infection, Infection, Human Immunodeficiency Virus
Interventions
GSK364735 oral solution and oral tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 28, 2026, 3:53 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers Results available

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection

NCT04925752
View directory record Official record
Conditions
Pre-Exposure Prophylaxis of HIV Infection
Interventions
Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years and older
Enrollment
3,292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
60
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 2 Interventional

A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment

NCT00000671
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
70
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 28, 2026, 3:53 PM EDT